On October 19, 2022, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. The shares began trading on the Nasdaq Global Market on October 20 under the ticker symbol “PRME.” Wilson Sonsini Goodrich & Rosati is advising Prime Medicine on all patent matters related to the transaction.

The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

The Wilson Sonsini team advising Prime Medicine on patent matters related to the IPO includes Lou Lieto, Clark Lin, Roshni Ghosh, Rachna Ujwal, David Habib, David Stanton, and Payal Vyas.

For more information, please see Prime Medicine’s news release.